‘SARMs Control Act’ Introduced in US Senate

In 2018 a new bill was introduced in the US Senate which affects the sales of SARMs in the U.S..

—————————————-
* * Jan 11 – UPDATE * *
—————————————-

We’re looking at the longest partial gov’t shutdown in history. The beginning of the fued started last December and may have preoccupied Congress enough to get even less done than usual.

It’s unclear whether or not a 2019 version will come forward, but we’re keeping a close watch on the SARMs Control Act situation.

SARMs remain in the FDA’s crosshairs and there seems to be no end to anti-SARM posts popping up on various health and fitness sites, mostly copy-and-pasted and generally regurgitating the same unscientific and unsourced misinformation about SARMs, such as “life-threatening reactions like liver damage” as copied in the White House press release shown below. Anyone who can produce for us a peer-reviewed study showing SARMs has caused liver damage gets 100,000 points ($1000) added to their account!

—————————————-
* * Dec 22 – UPDATE * *
—————————————-

After an extra week of fueding over border-wall spending and other high-level agenda items, the SARMs Control Act of 2018 is one of the bills that, fortunately, never got brought to a vote.

One would hope the ill-conceived bill might now go away forever, but SARMs remain in the FDA’s crosshairs as “we, the people” apparently need oversight when it comes to their research and use. Thus we expect to see a SARMs Control Act of 2019 in the not-too-distant future.

Fortunately, ammendments to the bill might now make it more of a label-compliance measure than a ban on selling, so SARMTECH and other sellers may be around awhile longer. Stay tuned… more to come.

—————————————-
* * Dec 15 – UPDATE * *
—————————————-

It’s Good news, Bad news, Good news…

Good news: the SARMs Control Act of 2018 did not get brought up for vote before this year’s final December 14th Senate session.

Bad news: turmoil and unfinished business is keeping the Senate going through next week at least, despite the upcoming holiday. “Both chambers are scheduled to be in session next week over hefty matters, including the budget and criminal sentencing reform. Votes remained scheduled.” Source: Cranky Congress Still Has Work to Do Before Wrapup.

Good news: Inclusions to the SARMs Control Act of 2018 could render it more of a label compliance measure than a strict ban on selling. In other words, SARMTECH and other sellers may be around awhile longer! Stay tuned… more to come.

—————————————-
* * Nov 30 – UPDATE * *
—————————————-

December 14th is the Senate’s final day in 2018 session (see Senate calendar) to vote on the SARMs Control Act of 2018.

It will affect all SARMs sales in the US. With new text inclusions introduced into the bill, it is uncertain at this time exactly how it will affect sales, but it appears some sellers will be able to continue to sell SARMs as Investigational New Drugs (IND’s).

—————————————

 


View Press Release

Hatch, Whitehouse Introduce Legislation to Empower DEA’s Regulation of SARMs

Washington, DC— US Senators Orrin Hatch (R-UT) and Sheldon Whitehouse (D-RI) introduced the SARMs Control Act of 2018. Selective androgen receptor modulators, or SARMs, are synthetic drugs designed to mimic the effects of testosterone. This bipartisan bill builds on the success of the Designer Anabolic Steroids Control Act of 2014 by extending the Drug Enforcement Administration’s authority to regulate anabolic steroids to include SARMs.

SARMs are associated with serious safety concerns, including the potential to increase the risk of heart attack or stroke and life-threatening reactions like liver damage. They are not approved by the Food and Drug Administration (FDA) for human use, they are illegally marketed and sold as dietary supplements, and they are banned in all professional and college sports.

“SARMs are synthetic drugs that have negative effects similar to those of anabolic steroids,” Hatch said. “Even though SARMS are not approved by the FDA for human use and pose the same safety risks as anabolic steroids, they have proliferated under a regime in which they are not subject to the same controls.  The SARMs Control Act closes this loophole to ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

“American consumers deserve to know if they’re buying seriously dangerous drugs slipped into everyday dietary supplements,” said Whitehouse.  “This bipartisan legislation will build on successful anti-designer steroids legislation we’ve already passed to help protect American consumers.”